Editorial Commentary
Bexmarilimab and azacitidine: promise for immunotherapy in myelodysplastic syndrome?
Annals of Blood
2026;
11:
20
.
(30 June 2026)
Editorial Commentary
Venetoclax and azacitidine in high-risk myelodysplastic syndromes: expectations vs. evidence
Annals of Blood
2026;
11:
19
.
(30 June 2026)
Editorial Commentary
Chronic graft-versus-host disease: toward mechanism-based prevention and treatment
Annals of Blood
2026;
11:
18
.
(30 June 2026)
Case Report
APTT dynamics after susoctocog alfa for early diagnostic support in suspected acquired hemophilia A: a case report
Annals of Blood
2026;
11:
17
.
(30 June 2026)
Case Report
Transfusion-acquired transient hemoglobinopathies: a case report and review of the literature
Annals of Blood
2026;
11:
16
.
(30 June 2026)
Case Report
Visual inspection of indeterminate crossmatch results prompted polyethylene glycol-enhanced antibody identification in a patient with poor hemoglobin response despite compatible transfusions: a case report
Annals of Blood
2026;
11:
15
.
(30 June 2026)
Review Article
Blood transfusion thresholds: a narrative review of the literature and recent guidelines
Annals of Blood
2026;
11:
14
.
(30 June 2026)
Review Article
Monoclonal B-cell lymphocytosis: what hematologists should know—a narrative review
Annals of Blood
2026;
11:
13
.
(30 June 2026)
Review Article
Transfusion practice in allogeneic hematopoietic stem cell transplantation: a narrative review of clinical guidelines and evidence gaps
Annals of Blood
2026;
11:
12
.
(30 June 2026)
Review Article
The history of hemoglobin-based oxygen carriers: a narrative review
Annals of Blood
2026;
11:
11
.
(30 June 2026)
